Equillium Inc.

The momentum for this stock is not very good. Equillium Inc. is not a good value stock. Equillium Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Equillium Inc..
Log in to see more information.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe...
EQ Fundamental Data by TradingView

News

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Business Wire Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...\n more…

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on August 30...\n more…

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Business Wire Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...\n more…

Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright
Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright

Ticker Report Equillium, Inc. (NASDAQ:EQ - Free Report) - HC Wainwright lowered their Q3 2024 earnings estimates for shares of Equillium in a report issued on Monday, August 19th. HC Wainwright analyst R...\n more…

HC Wainwright Comments on Equillium, Inc.'s Q3 2024 Earnings (NASDAQ:EQ)
HC Wainwright Comments on Equillium, Inc.'s Q3 2024 Earnings (NASDAQ:EQ)

Zolmax Equillium, Inc. (NASDAQ:EQ - Free Report) - Stock analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for Equillium in a report released on Monday, August 19th. HC...\n more…

Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share
Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share

Ticker Report Equillium, Inc. (NASDAQ:EQ - Free Report) - Analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Equillium in a report issued on Monday, August 19th. HC Wainwright...\n more…